Any current/future new fundraising through debt or equity?

No mention of any current or future fundraising through debt or equity was made in the transcript. The company maintains a very strong financial position with a very low debt-to-equity ratio of 0.01. The company follows a conservative borrowing approach, utilizing only letters of credit and bank guarantees without tapping into working capital limits. Capital expenditure plans, such as the Rs. 75-78 crore allocated for the Ambernath facility, are being funded internally without reference to new fundraising. Overall, the company appears focused on organic growth and internal cash flow for fundin

Any current/future capex/capital investment/strategic investment?

Ambernath facility CapEx is currently around Rs. 75-78 crores, down from an initial Rs. 100 crores allocation for FY25. Ambernath facility is under validation; production expected to start partially within 60 days. Ambernath focuses on CMO/CDMO, with multiple lines for injectables, tablets, capsules, plus R&D for contract research and API development. Module E expansion will add 500 KL capacity, doubling total capacity to 1,020 KL by end of September 2024. New product launches and capacity ramp-up are key catalysts for growth, indicating ongoing strategic investments. No current contribution f

Future growth expectations in sales/revenue/volumes?

The Company anticipates significant future growth driven by new product launches, especially in anesthetics, antidiabetics, and antianxiety therapeutic areas, targeting larger global markets. Expansion and ramp-up of Module E will double total capacity to 1,020 KL by September, supporting higher volumes. CDMO and CMO business contributions expected to start by Q3 FY25, targeting around 20% of total revenue in the next 3-4 years. Increased presence in regulated markets like Europe, North America, and Latin America expected to boost revenue with higher-margin opportunities. Brazil and Mexico mar

Future growth expectations in earnings/operating earnings/profits/EPS?

Supriya Lifescience expects a revenue growth of around 20% for the medium term (this and next financial year), with potential upside risk due to new contracts and product launches. EBITDA margins are anticipated to remain upward trending, with a conservative guidance of 30%+ margin, possibly higher post Q2 FY25 results. New product launches in anesthetics, antianxiety, and antidiabetic categories, targeting large-volume global markets, will contribute to growth in coming quarters. Expansion of CDMO/CMO business is expected, with CMO projected to contribute about 20% of revenue in 3-4 years. Th

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide specific quantitative details on the current or expected orderbook or pending orders. However, several points indicate robust business momentum and growing contracts: - The company has two active CMO contracts, including DSM Firmenich, currently supplying validation quantities and food application demand. - Progress on new CMO/CDMO contracts is ongoing, with validation volumes expected in upcoming quarters. - New product launches and contracts are expected to contribute positively in the next 1.5 years. - CDMO business contribution is anticipated to reac

Supriya Lifesci.Q1 FY25Pharmaceuticals & Biotechnology

Supriya Lifesci. Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹931P/E: 39.9Market Cap: ₹7.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The Company anticipates significant future growth driven by new product launches, especially in anesthetics, antidiabetics, and antianxiety therapeutic areas, targeting larger global markets.
Expansion and ramp-up of Module E will double total capacity to 1,020 KL by September, supporting higher volumes.
CDMO and CMO business contributions expected to start by Q3 FY25, targeting around 20% of total revenue in the next 3-4 years.
Increased presence in regulated markets like Europe, North America, and Latin America expected to boost revenue with higher-margin opportunities.
Brazil and Mexico markets offer good opportunity due to new GMP certification ultimatum effective by December 2024, driving increased basket and revenue.
Oral cancer kit commercialization and patent approvals are anticipated in 1-1.5 years, with revenue contributions expected in the coming quarters but full-scale commercial production over 2 years.
Overall EBITDA margins expected to remain trending upwards, with margin normalization around 28-30% as new products scale.

Margin guidance

Category 1

Supriya Lifescience expects a revenue growth of around 20% for the medium term (this and next financial year), with potential upside risk due to new contracts and product launches.
EBITDA margins are anticipated to remain upward trending, with a conservative guidance of 30%+ margin, possibly higher post Q2 FY25 results.
New product launches in anesthetics, antianxiety, and antidiabetic categories, targeting large-volume global markets, will contribute to growth in coming quarters.
Expansion of CDMO/CMO business is expected, with CMO projected to contribute about 20% of revenue in 3-4 years.
The ramp-up of new capacities (doubling to 1,020 KL by September 2024) will be a key catalyst for future growth.
Oral cancer kit and other novel technologies are in pipeline; commercial production may take 2 years.
Overall, growth in earnings and profitability is expected driven by better product mix, market expansion, and operational efficiency.

See what Supriya Lifesci. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No mention of any current or future fundraising through debt or equity was made in the transcript.
The company maintains a very strong financial position with a very low debt-to-equity ratio of 0.01.
The company follows a conservative borrowing approach, utilizing only letters of credit and bank guarantees without tapping into working capital limits.
Capital expenditure plans, such as the Rs. 75-78 crore allocated for the Ambernath facility, are being funded internally without reference to new fundraising.
Overall, the company appears focused on organic growth and internal cash flow for funding expansions rather than raising fresh debt or equity.

Order book

The transcript does not provide specific quantitative details on the current or expected orderbook or pending orders.
However, several points indicate robust business momentum and growing contracts:
- The company has two active CMO contracts, including DSM Firmenich, currently supplying validation quantities and food application demand.
- Progress on new CMO/CDMO contracts is ongoing, with validation volumes expected in upcoming quarters.
- New product launches and contracts are expected to contribute positively in the next 1.5 years.
- CDMO business contribution is anticipated to reach about 20% of total revenue within the next 3 to 4 years.
- The Ambernath facility, coming online soon, will enable additional CMO, CDMO, and contract research projects.
- Discussions and activities on whey protein exports and other contracts are commencing.
Overall, order inflow seems promising, with validation and production phases progressing for multiple new contracts.

See what Supriya Lifesci. management said on order book — free account, 30 seconds.

Capex plans

Yes

Ambernath facility CapEx is currently around Rs. 75-78 crores, down from an initial Rs. 100 crores allocation for FY25.
Ambernath facility is under validation; production expected to start partially within 60 days.
Ambernath focuses on CMO/CDMO, with multiple lines for injectables, tablets, capsules, plus R&D for contract research and API development.
Module E expansion will add 500 KL capacity, doubling total capacity to 1,020 KL by end of September 2024.
New product launches and capacity ramp-up are key catalysts for growth, indicating ongoing strategic investments.
No current contribution from CMO/CDMO, but expected to reach ~20% of revenue within 3-4 years.

Track Supriya Lifesci. — get its next earnings analysis in your feed

How does Supriya Lifesci. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSupriya Lifesci.

Rev 2Mar 1

See where Supriya Lifesci. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Supriya Lifesci. rank in Pharmaceuticals & Biotechnology?

Compare Supriya Lifesci. against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Supriya Lifesci.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →